Status | Study |
Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Adrenocortical Carcin Date: 2017-02-08 |
Recruiting |
Study Name: Investigation of the Genetics of Hematologic Diseases Condition: Bone Marrow Failure Syndromes Erythrocyte Disorder Leukocy Date: 2016-03-16 |
Recruiting |
Study Name: Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Condition: Primary Immune Deficiency Disorders Hemophagocytic Lymphohistiocytosis Date: 2014-08-28 Interventions: Biological: BPX-501 and AP1903 Single administration of BPX-501 T cells post partially-mismatched, relat |
Recruiting |
Study Name: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Condition: Dyskeratosis Congenita Aplastic Anemia Date: 2014-06-10 Interventions: Drug: Alemtuzumab Alemtuzumab |
Recruiting |
Study Name: Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT Condition: Primary Immunodeficiency Syndromes Congenital Bone Marrow Failure Syndromes Date: 2013-10-10 Interventions: Drug: Hydroxyurea Hydroxyurea |
Recruiting |
Study Name: BMT Abatacept for Non-Malignant Diseases Condition: Hurler Syndrome Fanconi Anemia Glanzmann Thrombasthenia Date: 2013-07-24 Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis |
Recruiting |
Study Name: Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita Condition: Dyskeratosis Congenita Hoyeraal Hreidarss Date: 2012-08-06 Interventions: Biological: alemtuzumab Condit |
Suspended |
Study Name: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Condition: Thalassemia Sickle Cell Disease Glanzmann Thrombasthenia Date: 2010-09-15 Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep |
Terminated |
Study Name: Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita Condition: Fanconi Anemia Dyskeratosis Congenita Date: 2009-10-22 Interventions: Drug: danazol Dosage is done according to weight; capsules are 50, 100, 200 mg |
Recruiting |
Study Name: Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Condition: Non-Malignant Date: 2009-06-11 Interventions: Procedure: Allogeneic Bone Marrow Transplantation |